Occurrence and management of hepatitis B virus reactivation following kidney transplantation

Clinical Nephrology

Volumn 49, Issue 6, 1998, Pages 385-388

  Grotz, W ^a,c   Rasenack, J ^b   Benzing, T ^a   Berthold, H ^b   Peters, T ^b   Walter, E ^b   Schollmeyer, P ^a   Rump, L C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Department of Hepatology ^*  (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Foscarnet; Hepatitis B; Liver failure; Reactivation; Transplantation

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; ANTIVIRUS AGENT; AZATHIOPRINE; FOSCARNET; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS C ANTIBODY; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CASE REPORT; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER FAILURE; LIVER FUNCTION TEST; PROTHROMBIN TIME; VIRUS GENOME; VIRUS REACTIVATION;

ADULT; FEMALE; HEPATITIS B; HUMANS; KIDNEY TRANSPLANTATION; RECURRENCE;

EID: 0031841955     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Angus P, Richards M, Bowden S, Ireton J, Sinclair R, Jones R, Locarnini S 1993 Combination of antiviral therapy controls severe post liver transplant recurrence of hepatitis B virus infection. J Gastroenterol Hepatol 8: 353-357
2. Antinori S, Esposito K, Monteforte A, Moroni M 1993 Foscarnet treatment of chronic hepatitis B in a HIV positive patient. J Hepatol 18: 255-256
3. Bain VG, Daniels HM, Chanas A, Alexander GJM, Williamas R 1989 Foscarnet therapy in chronic hepatitis B virus e antigen carriers. J Med Virol 29: 152-155
4. Bell DM, Shapiro CN, Culver DH, Martone WJ, Curran JW, Hughes JM 1992 Risk of hepatitis B and human immunodeficiency virus transmission to a patient from an infected surgeon due to percutaneous injury during an invasive procedure: estimates based on a model. Infect Agents Dis 1: 263-269
5. Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, Saracco G, Verme G, Will H, Bonino F 1991 Wildtype and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 88: 4186-4190
6. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC 1989 Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2: 588-591
7. Chen P, Fan S, Liu JH, Chiou TJ, Hsieh SRK, Liu RS, Tzeng CH 1993 Reactivation of hepatitis B virus in two chronic GVHD patients after transplant. Int J Hematol 58: 183-188
8. Degos F, Lugassay C, Degott C, Debure A, Carnot F, Thiers V,Tiollais P, Kreis H, Brechot C 1998 Hepatitis B and hepatitis B-related viral infection in renal transplant recipients. Gastroenterol 94: 151-156
9. Dusheiko GM, Song E, Bowyer S, Whittcutt M, Maier G, Meyers A, Kew MC 1983 Natural history of hepatitis B virus infection in renal transplant recipients - a fifteen-year follow-up. Hepatology 3: 330-336
10. Grotz W, Gondolf K, Rasenack J, Berthold H, Rump LC, Schollmeyer P 1995 Imminent Liver Failure in a Hepatitis B Positive Renal Allograft Recipient - Successful Therapy with Interferon-alpha. Nephrol Dial Transplant 10: 1932-1934
11. Grumayer R, Panzer S, Ferenci P, Gadner H 1989 Recurrence of hepatitis B in children with serologic evidence of past hepatitis B virus infection undergoing antileukemic chemotherapy. Hepatology 8: 232-235
12. Harpaz K, Von Seidlein L, Averhoff FM, Tormey MP, Sinha SD, Kotsoupoulou K, Lambert SB, Robertson BH, Cherry JD, Shapiro CN 1996 Transmission of hepatitis B virus to multiple patients from a surgeon of inadequate infection control. N Engl J Med 334: 549-554
13. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ 1994 Enhanced replication of a hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virology 68: 1651-1659
14. Kosaka Y, Takase K, Kojima M, Shimizu M, Inoue K, Yoshiba M, Tanaka S, Akahane Y, Okamoto H, Tsuda F, Miakawa Y, Mayumi M 1991 Fulminant hepatitis B: Induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterol 100: 1087-1094
15. Lam K, Lai C, Trepo C, Wu P 1981 Deleterious effect of prednisone in HBsAg-positive chronic active hepatitis. N Engl J Med 304: 380-386
16. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E 1991 A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 324: 1705-1709
17. Locarnini S 1991 Chronic hepatitis B virus infection: design of new antiviral agents. J Gastroenterol Hepatol 6 (suppl 1): 18-22
18. Locasciulli A, Santamaria M, Masera C, Schiavon E, Alberti A, Realdi G 1985 Hepatitis B virus markers in children with acute leukaemia: the effect of chemotherapy. J Med Virol 15: 29-33
19. Loetscher R, Brunner FP, Harder F, Thiel G 1983 Withdrawal of azathioprine in renal transplant patients with chronic active hepatitis: is it wise or not? Nephron 33: 150-155
20. McMillan JS, Shaw T, Angus PW, Locarnini SA 1995 Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22: 36-43
21. Ogata N, Miller RH, Ishak KG, Purcell RH 1993 The complete oligonucleotide sequence of a precore mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 194: 263-276
22. Ohkawa K, Hayashi N, Yuki N, Masuzawa M, Kato M, Yamamoto K, Hosotsubo H, Deguchi M, Katayama K, Kasahara A, Fusamoto H, Kamada T 1995 Long-term follow-up of hepatitis B virus and hepatitis C virus replicative levels in chronic hepatitis patients coinfected with both viruses. J Med Virol 46: 258-264
23. Omata M, Chata T, Yokosuka O, Hosoda K, Ohto M 1991 Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 324: 1699-1704
24. Parfrey P, Farge D, Forbes C, Dandavino R, Kenick S, Guttmann R 1985 Chronic hepatitis in endstage renal disease: Comparison of HBsAg-negative and HBsAg-positive patients. Kidney Int 28: 959-967
25. Peters T, Mohr L, Scheiffele F, Schlayer HJ, Preisler S, Berthold H, Gerok W, Rasenack J 1994 Antibodies and viremia in acute post-transfusion hepatitis C: a prospective study. J Med Virol 42: 420-427
26. Pontisso P, Ruvoletto MG, Fattovich G, Chemello L, Gallorini A, Ruol A, Alberti A 1993 Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterol 105: 1529-1533
27. Price JS, France AJ, Moaven LD, Welsby PD 1986 Foscarnet in fulminant hepatitis B. Lancet 2: 1273
28. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV 1996 The hepatitis B virus persists for decades after patients recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nature Medicine 2: 1104-1108
29. Thomas HC, Montano L, Goodall A, de Koning R, Oladapo J, Wiedmann KH 1982 Immunological mechanisms in chronic hepatitis B virus infection. Hepatology 2 (suppl): 116-121
30. Tur Kaspa R, Burk RD, Shaul Y, Moore DD, Shafritz DA 1986 Hepatitis B virus DNA contains a glucocorticoid response element. Proc Natl Acad Sci USA 83: 1627-1631
31. Tur Kaspa R, Laub O 1990 Corticosteroids stimulate hepatitis B virus DNA, mRNA, and protein production in a stable expression system. J Hepatol 11: 34-36
32. Webster A, Brenner MK, Prentice HG, Griffiths PD 1989 Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant 4: 207-208